Eton Pharmaceuticals, Inc. (ETON) vs Xeris Biopharma Holdings, Inc. (XERS)
- Eton Pharmaceuticals, Inc. ETON 50.40 −1.81%
- Xeris Biopharma Holdings, Inc. XERS 10.28 +2.09%
Eton Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Xeris Biopharma Holdings, Inc. is the larger, with a market value of $1.8B against $1.5B — 1.3× the size. Xeris Biopharma Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Eton Pharmaceuticals, Inc. trades at 107×. Eton Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 81.5% against 36.3%. Eton Pharmaceuticals, Inc. has the higher net margin (12.0% vs −5.12%) and the higher return on invested capital (21.4% vs 18.9%). Across the 18 metrics below, Eton Pharmaceuticals, Inc. leads on 9 and Xeris Biopharma Holdings, Inc. on 9.
Valuation
Profitability
| Metric | ETON | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 57.87% | 86.58% | 53.94% |
| Operating margin | 15.44% | 10.91% | 0.00% |
| Net margin | 12.02% | (5.12%) | 0.00% |
| Free cash flow margin | (7.94%) | 16.60% | 0.00% |
| Return on equity | 35.97% | 118.22% | (0.40%) |
| Return on assets | 11.67% | (4.60%) | (3.32%) |
| Return on invested capital | 21.39% | 18.88% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack